^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MB-101

i
Other names: IL13Ra2-specific CAR, MB-101, IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocyte therapy, IL13Rα2‐specific CAR T cells
Associations
Company:
Fortress
Drug class:
IL-13-targeted CAR-T immunotherapy
Associations
17d
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600 • CD123 expression
|
cyclophosphamide • fludarabine IV • MB-101
24d
NCI-2014-01488: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
P1, N=65, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
|
CD123 expression
|
MB-101
over1year
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
P1, N=82, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
Trial completion date • Trial primary completion date
|
IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
|
CD123 expression
|
MB-101
almost2years
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
P1, N=82, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
Trial completion date • Trial primary completion date
|
IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
|
CD123 expression
|
MB-101
over2years
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (clinicaltrials.gov)
P1, N=30, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Nov 2025 | Trial primary completion date: Dec 2023 --> Nov 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
CD123 expression
|
MB-101
4years
Clinical • Enrollment open • CAR T-Cell Therapy
|
BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
over4years
Clinical • Trial suspension • CAR T-Cell Therapy
|
BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
almost5years
Clinical • Enrollment open • CAR T-Cell Therapy
|
BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous